CTOs on the Move

Unlearn

www.unlearn.ai

 
Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTsTM, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn`s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.unlearn.ai
  • 75 Hawthorne Street Suite 560
    San Francisco, CA USA 94105
  • Phone: n/a

Executives

Name Title Contact Details
Alex Lang
Vice President of Technology Profile

Similar Companies

Genemed Synthesis

Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA Phenomics

DNA Phenomics is a Bowling Green, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gameto

Gameto is a biotechnology company that uses cell engineering to develop novel therapeutics for the diseases of the female reproductive system.

CorneaGen

CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.

Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.